M Battegay
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
Zinkernagel C, Ledergerber B, Battegay M, Cone R, Vernazza P, Hirschel B, Opravil M. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. AIDS (London, England) 1999; 13:1587-9.
20.08.1999Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
20.08.1999AIDS (London, England) 1999; 13:1587-9
Zinkernagel C, Ledergerber B, Battegay M, Cone R W, Vernazza Pietro, Hirschel B, Opravil M
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Bassetti S, Bernasconi E, Vernazza P, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9.
01.06.1999Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
01.06.1999Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9
Bassetti S, Bernasconi E, Vernazza Pietro, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. The New England journal of medicine 1999; 340:1301-6.
29.04.1999Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
29.04.1999The New England journal of medicine 1999; 340:1301-6
Furrer H, Flepp M, Rickenbach M, Vernazza Pietro, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
13.03.1999Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
13.03.1999Lancet 1999; 353:863-8
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza Pietro, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
Bisset L, Cone R, Huber W, Battegay M, Vernazza P, Weber R, Grob P, Opravil M. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:2115-23.
12.11.1998Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
12.11.1998AIDS (London, England) 1998; 12:2115-23
Bisset L R, Cone R W, Huber W, Battegay M, Vernazza Pietro, Weber R, Grob P J, Opravil M